- ROUNDTABLE: Improving patient outcomes, controlling costs with OTCs
- Consumer trust intact as McNeil brands like Tylenol return back to shelf
- Q&A: Genetic profiling with Dr. Anita Goel of Nanobiosym
- J&J's return to market of several iconic OTC brands a success
- Report: Dietary supplements utilized as preventive health care can save health system tens of billions of dollars
NEW YORK — Johnson & Johnson on April 4 will install Pat Mutchler as head of the McNeil Consumer Healthcare unit, according to a Wednesday evening Associated Press report.
According to the report, Johnson & Johnson said the changes will allow the company to "give focused attention to quality and compliance, and the critical task of restoring McNeil Consumer Healthcare brands."
McNeil has had to announce some 20 recalls of iconic brands, including Tylenol, Motrin, Benadryl and Rolaids, since September 2009. J&J reported Mutchler will be in charge of the McNeil business. He also will lead other divisions, including McNeil Nutritionals, Wellness & Prevention and the company's joint venture with Merck.
The global consumer businesses will be organized by region — North America, Latin America, Asia-Pacific and Europe/Middle East/Africa. The AP reported that Grace Castano will lead J&J’s Asia-Pacific business, Jose Justino will lead the Europe/Middle East/Africa unit, Roberto Marques will be chairman for North America and Susan Rivetti will be in charge of the Latin America division.